

## Bone density in transfusion dependent thalassemia patients in Urmia, Iran

Valizadeh N MD<sup>1\*</sup>, Farrokhi F MD<sup>2</sup>, Alinejad V MSc<sup>3</sup>, Said Mardani SM MD<sup>4</sup>, Valizadeh N MD<sup>5</sup>, Hejazi S MD<sup>6</sup>, Noroozi M MD<sup>7</sup>

1. Assistant professor of Hematology/Medical Oncology, Urmia University of Medical Sciences, Urmia, Iran

2. Medical Student, Urmia University of Medical Sciences, Urmia, Iran

3. MSc. of Biostatistics, Patient Safety Research Center, Urmia University of Medical Sciences, Urmia, Iran

4. Assistant professor of Rheumatology, Urmia University of Medical Sciences, Urmia, Iran

5. Assistant professor of Endocrinology and Metabolism, Urmia University of Medical Sciences, Urmia, Iran

6. Assistant professor of Pediatric Hematology/Medical Oncology, Department of pediatric hematology, Motahari hospital, Urmia university of medical sciences, Urmia, Iran

7. Assistant professor of Pediatric Hematology/Medical Oncology, Department of pediatric hematology, Motahari hospital, Urmia University of medical sciences, Urmia, Iran.

Received: 25 October 2013

Accepted: 30 January 2014

### Abstract

#### Background

Patients with thalassemia major and intermedia are susceptible to osteopenia and osteoporosis. The mechanism of osteoporosis in these patients is multifactorial. Transfusion related iron overload in endocrine organs leads to impaired growth hormone secretion, diabetes mellitus, hypothyroidism, hypoparathyroidism, lack of sex steroids and vitamin D deficiency that contribute to impairment in achieving an adequate bone mass. The aim of this study was assessment of frequency of bone loss in patients with thalassemia major and intermedia in Urmia City of West Azerbaijan, Iran

#### Materials and Methods

In this cross sectional descriptive study, 10 patients (lower than 18 y/o) with transfusion dependent thalassemia attending to Motahari and Emam Khomeini hospitals in Urmia city of Iran were enrolled and scanned for Bone Mineral Density (BMD) starting at around 10 years old.

#### Results

Ten patients (6 male and 4 female) with transfusion dependent thalassemia ( $\beta$ -thalassemia major and

intermedia) aged 13 to 17 years in Urmia city of Iran were enrolled. Mean age of patients was  $15.1 \pm 3.7$  year old. Among them, 8 patients (80%) had low BMD and 2 of them (20%) had normal BMD in lumbar spine. Only 30% of patients had low BMD in the neck of femur.

#### Conclusion

We should perform annual BMD in patients with thalassemia major and intermedia and hemoglobin H disease in age of higher than 8 year old and treat low BMD with administration of bisphosphonate, calcium and vitamin D supplements. Medical consultation with a rheumatologist and /or an endocrinologist should be performed in these patients. Changing lifestyle with mild daily exercise, adequate calcium containing foods, avoiding heavy activities, stop smoking, iron chelation therapy in adequate dosage, early diagnosis and treatment of endocrine insufficiency and regular blood transfusions can help to achieve an optimal bone density in these patients.

#### Keywords

Thalassemia, Bone mineral density, Osteoporosis, Bone Loss

#### Corresponding author:

Valizadeh N MD, Assistant professor of Hematology/Medical Oncology, Urmia University of Medical Sciences, Urmia, Iran, email: nседaha0@gmail.com.

#### Introduction

Patients with transfusion dependent thalassemia are at risk to osteopenia and osteoporosis. The pathogenesis of osteoporosis in this group is multifactorial and is included environmental, acquired and genetic factors. Transfusion related iron deposition in endocrine

glands can cause impaired growth hormone (GH) secretion, lack of sex steroids, diabetes mellitus, hypothyroidism, hypoparathyroidism and vitamin D deficiency and lead to bone loss. Uncontrolled erythropoiesis and progressive marrow expansion are

other causes of osteoporosis in thalassemia major and intermedia patients. Osteoporosis is a side effect of iron toxicity on osteoblasts and also Deferoxamine, an iron chelator which is used in these patients. (1-13).

A study established reduced bone formation rate in Thalassemia major patients (14).

The aim of this study was to assess the frequency of bone loss in patients with thalassemia major and intermedia in Urmia city of West Azerbaijan, Iran.

Patients were scanned for bone mineral density (BMD) at anteroposterior lumbar spine (L1-L4) and femoral neck, using dual energy X-ray absorptiometry. The results of a bone density test are presented as a T or a Z score. T-score is comparison of the bone density with what is normally expected in a healthy young with same sex and Z-score is the number of standard deviations above or below what is normally expected for someone with same age, sex, weight, and ethnic origin.

The World Health Organization (WHO) defines osteopenia as Bone Mineral Density (BMD) T-score of between -1 to -2.5. The WHO defines osteoporosis as BMD T-Score of lower than -2.5. (15) Because low bone mass can occur at a much younger age in thalassemia than in the general population, Z-score is used to assess bone mass in patients with thalassemia who are younger than 30 years old. Z score of lower than -2 considered as low BMD.

## Materials and Methods

In this cross sectional descriptive study, 10 patients with transfusion dependent thalassemia younger than 18 years old attending to Motahari and Emam Khomeini hospitals in Urmia city were enrolled. Bone Mineral Density (BMD) was performed on an annual basis starting at around 10 years old. BMD was measured by a dual energy x-ray absorptiometry test that is commonly called a DEXA scan.

## Statistical analysis

The results of BMD measurement enable us to determine T-score or Z-score and to determine if they have osteopenia or osteoporosis.

## Results

10 patients (6 male and 4 female) with transfusion dependent thalassemia ( $\beta$ -thalassemia major and intermedia) aged 13 to 17 years were enrolled. Mean age of patients was  $15.1 \pm 3.7$  year's old and mean value of the height was  $141 \pm 17.56$  cm. Hemoglobin and ferritin level of patients were  $9.56 \pm 4.7$  g/dl and  $1421.1 \pm 371.81$  ng/ml. Among 10 patients, 8 patients (80 %) had low BMD and 2 patients (20%) had normal BMD according to their Z-scores in lumbar spine. Only 30% of patients had low BMD in the neck of femur (Table I).

Table I: Demographic features of patients

Patient	Age	Gender	Height (cm)	Disease	Hemoglobin (gr/dl)	Ferritin (ng/ml)	Z score of lumbar spine	Z score of femoral neck
1	15	male	137	Major thalassemia	9.2	1400	-2.2	-1.3
2	15	male	134	Major thalassemia	9.4	1020	-1.3	-1.2
3	16	male	138	Major thalassemia	10.2	1930	-3.0	-2.4
4	17	male	149	Major thalassemia	10.2	1700	-4.2	-2.2
5	14	female	133	Thalassemia intermedia	9.4	1110	-2.0	-1.5
6	15	male	138	Major thalassemia	9.3	930	-3.3	-3.0
7	13	female	135	Major thalassemia	10.2	1900	-0.8	-0.7
8	16	male	173	Major thalassemia	9.3	1200	-3	-1.3
9	16	female	139	Major thalassemia	10	1800	-2.5	-1.3
10	14	female	135	Major thalassemia	8.9	1256	-2.3	-1.8

## Discussion

Predisposing factors of osteoporosis in patients with transfusion related thalassemia are: endocrine insufficiency due to iron overload (delay in sexual maturation, hypoparathyroidism, hypothyroidism, diabetes mellitus and growth hormone insufficiency), direct iron toxicity on osteoblasts, progressive marrow expansion due to accelerated hematopoiesis and side effect of deferoxamine which is used as an iron chelator (1-5)

Wonke et al, studied the polymorphism at the Sp1 location of the collagen type Ia1 (COLIA 1) gene which is the major bone matrix protein and found that approximately 30% of the thalassemia major patients were heterozygotes and 4% were homozygotes for the Sp1 polymorphism. They concluded that men with thalassemia major carrying the Sp1 mutation may develop severe osteoporosis of the spine and the hip more frequently than patients who do not carry this mutation (16).

Detection of COLIA 1 polymorphism may have a role in identifying thalassemia patients that are susceptible to develop osteoporosis and pathologic fractures (17).

Voskaridou E, et al studied frequency of osteopenia or osteoporosis in well treated Thalassemia patients and found that approximately 40 to 50% of them involved with this morbidity (1).

Hatice Hamarat, et al studied frequency of osteoporosis in thalassemia major patients in Turkey and showed that among 25 patients with thalassemia major (14 men, 11 women) 16 patients had osteoporosis, whereas 9 patients had osteopenia (18).

Salim M AL Jadir, et al conducted a study on thalassemia patients and found that the prevalence of osteoporosis in thalassemia Iraqi patients was 67.5%, while osteopenia was found in 9.4% and normal BMD in 22.9% (19).

Karimi M, et al studied for Bone Mineral Density in Beta-Thalassemia Major and Intermedia and showed that Patients with thalassemia major and intermedia, younger than 20 yr., had lower BMD and BMC in the lumbar region (20).

In our study, 80% of transfusion dependent thalassemia patients in Urmia city had low BMD thus; we should be aware and inform thalassemia patients about complications of osteoporosis such as bony fractures. Changing in life style is recommended to all transfusion dependent thalassemia patients with low BMD.

## Conclusion

Among 10 patients below than 18 y/o in Urmia city, 8 patients (80 %) had low BMD and 2 patients (20%) had normal BMD in lumbar spine according to their Z-scores. We should check transfusion dependent thalassemia patients with age more than 8 years old

for bone loss by annual BMD and treat osteoporosis and osteopenia with administration of bisphosphonate, calcium and vitamin D supplements. Medical consultation with a rheumatologist and /or an endocrinologist should be performed in transfusion dependent thalassemia patients with bone loss. Changing of lifestyle with mild daily exercise and adequate Calcium rich foods (such as milk, yogurt and cheese, Dark green leafy vegetables such as broccoli, nuts, peas and baked beans) can prevent bone loss and fractures. Patients with osteoporosis should avoid heavy activities and stop smoking. Iron chelation therapy in adequate dosage can prevent iron toxicity on osteoblasts. Early diagnosis and treatment of endocrine insufficiencies can prevent bone loss. Regular blood transfusions help for prevention of progressive bone marrow expansion.

## Acknowledgement

This work is supported by Urmia University of Medical Sciences.

## Conflict of Interest

The authors have no conflict of interest.

## Reference

1. Voskaridou, E. & E. Terpos. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. *Br J Haematol.* 2004;127(2):127-39.
2. Garofalo F1, Piga A, Lala R, Chiabotto S, Di Stefano M, Isaia GC. Bone metabolism in thalassemia. *Ann. N.Y. Acad. Sci.* 1998; 850: 475-478.
3. Voskaridou, E. & E. Terpos. Pathogenesis and management of osteoporosis in thalassemia. *Pediatr. Endocrinol. Rev.* 2008. 6(Suppl. 1): 86-93.
4. Terpos E, Voskaridou E. Treatment options for thalassemia patients with Osteoporosis. *Ann. N.Y. Acad. Sci.* 2010;237-43
5. Olivieri, N.F. The beta-thalassaemias. *N. Engl. J. Med.* 1999;341(2): 99-109.
6. Jensen CE1, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, et al. High prevalence of low bone mass in thalassaemia major. *Br J Haematol.* 1998;103(4):911-5
7. Skordis N1, Michaelidou M, Savva SC, Ioannou Y, Rousounides A, Kleanthous M, et al. The impact of genotype on endocrine complications in thalassaemia major. *Eur J Haematol.* 2006;77(2):150-6.
8. Gaudio A, Morabito N, Xourafa A, Curro M, Caccamo D, Ferlazzo N, et al. Role of genetic pattern on bone mineral density in thalassaemic patients. *Clin Biochem.* 2010;43(10-11):805-7
9. Anapliotou M. L., Kastanias I. T., Psara P,

- Evangelou E. A.,Liparaki M, and Dimitriou P., The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches, *ClinEndocrinol (Oxf)*. 1995; 42(3):279-87
10. Skordis N., Efstathiou E., Kyriakou A., and ToumbaM.,“Hormonal dysregulation and bones in thalassaemia—an overview,” *Pediatric Endocrinology Reviews* , 2008.vol. 6, supplement 1, pp. 107–115
11. Olivieri NF1, Koren G, Harris J, Khattak S, Freedman MH, Templeton DM,et all., Growth failure and bony changes induced by deferoxamine, *Am J PediatrHematolOncol*. 1992;14(1):48-56
12. De Virgiliis S1, Congia M, Frau F, Argiolu F, Diana G, CuccaF,etall.Deferoxamineinduced growth retardation in patients with thalassaemia major. *J Pediatr*. 1988; 113(4):661-9.
13. Wonke, B. Bone disease in beta-thalassaemia major. *Br J Haematol*. 1998;103(4):897-901
14. Mahachoklertwattana P1, Sirikulchayanonta V, Chuansumrit A, Karnsombat P, Choubtum L, Sriphrapadang A, et all.Bonehistomorphometry in children and adolescents with beta-thalassaemia disease: iron-associated focal osteomalacia. *J ClinEndocrinolMetab*. 2003;88(8):3966-72
15. Binkley, N.C., P. Schmeer, R.D. Wasnich & L. Lenchik. What are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-Caucasians? *J ClinDensitom*. 2002;5: 19-27
16. Wonke B1, Jensen C, Hanslip JJ, Prescott E, Lalloz M, Layton M, et all. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. *J PediatrEndocrinolMetab*. 1998;11Suppl 3:795-801.
17. Perrotta S1, Cappellini MD, Bertoldo F, Servedio V, Iolascon G, D'Agruma L, et all. Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. *Br JHaematol*. 2000. 111(2): 461–6.
18. Hatice Hamarat, Göknur Yorulmaz, Uğur Bilge, Özlem Demirpençe. Determination of osteoporosis frequency among the thalassaemia major patients. *Turkish journal of family practice*, 2013; 17(4): 153-6.
19. Salim M AL Jadir, Mohamed Z Jalal, Median F AL Ghreer, Mozahem S AL Hamdani , Wamid R AL Omaree. Osteoporosis in Iraqi patients with thalassaemia. *Arthritis Research & Therapy* 2012, 14(Suppl 1):P4
20. Karimi M, Fotouhi Ghiam A, Hashemi A, Alinejad S, Soweid M, Kashef S. Bone mineral density in beta-thalassaemia major and intermedia. *Indian Pediatr*. 2007;44(1):29-32.